ATE513555T1 - Pharmazeutische kombination aus g-csf und plgf für blutstammzellen - Google Patents

Pharmazeutische kombination aus g-csf und plgf für blutstammzellen

Info

Publication number
ATE513555T1
ATE513555T1 AT04763431T AT04763431T ATE513555T1 AT E513555 T1 ATE513555 T1 AT E513555T1 AT 04763431 T AT04763431 T AT 04763431T AT 04763431 T AT04763431 T AT 04763431T AT E513555 T1 ATE513555 T1 AT E513555T1
Authority
AT
Austria
Prior art keywords
csf
stem cells
plgf
blood stem
pharmaceutical combination
Prior art date
Application number
AT04763431T
Other languages
English (en)
Inventor
Alessandro GIANNI
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Application granted granted Critical
Publication of ATE513555T1 publication Critical patent/ATE513555T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04763431T 2003-07-29 2004-07-23 Pharmazeutische kombination aus g-csf und plgf für blutstammzellen ATE513555T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
ATE513555T1 true ATE513555T1 (de) 2011-07-15

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763431T ATE513555T1 (de) 2003-07-29 2004-07-23 Pharmazeutische kombination aus g-csf und plgf für blutstammzellen

Country Status (21)

Country Link
US (1) US20070036747A1 (de)
EP (1) EP1660115B1 (de)
JP (1) JP4855253B2 (de)
KR (1) KR101192136B1 (de)
CN (1) CN100534528C (de)
AT (1) ATE513555T1 (de)
AU (1) AU2004262909B2 (de)
BR (1) BRPI0412989A (de)
CA (1) CA2526244C (de)
DK (1) DK1660115T3 (de)
ES (1) ES2369487T3 (de)
IL (1) IL173369A (de)
MX (1) MXPA06000017A (de)
NO (1) NO20060955L (de)
NZ (1) NZ543612A (de)
PL (1) PL1660115T3 (de)
PT (1) PT1660115E (de)
RU (1) RU2351357C2 (de)
SI (1) SI1660115T1 (de)
WO (1) WO2005014023A1 (de)
ZA (1) ZA200509361B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006218711B2 (en) 2005-03-02 2010-11-11 University Of Maryland, Baltimore Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
CA2770092A1 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
KR102503695B1 (ko) 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
EP4463135A2 (de) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Verfahren zur ex-vivo-dosierung und -verabreichung von lipidpartikeln oder viralen vektoren sowie entsprechende systeme und verwendungen
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4716750A1 (de) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem-fusogene und verwandte lipidpartikel
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
EP1147777A1 (de) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Kombination von Defibrotid und G-CSF und ihre Verwendung zur Aktivierung der hämatopoiestischen Vorläuferzellen
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells

Also Published As

Publication number Publication date
CN100534528C (zh) 2009-09-02
NZ543612A (en) 2008-03-28
EP1660115A1 (de) 2006-05-31
RU2006106228A (ru) 2007-09-10
ZA200509361B (en) 2007-03-28
US20070036747A1 (en) 2007-02-15
RU2351357C2 (ru) 2009-04-10
AU2004262909A1 (en) 2005-02-17
IL173369A0 (en) 2006-06-11
NO20060955L (no) 2006-02-27
PL1660115T3 (pl) 2011-11-30
CA2526244A1 (en) 2005-02-17
BRPI0412989A (pt) 2006-10-03
IL173369A (en) 2010-12-30
MXPA06000017A (es) 2006-03-21
JP2007500157A (ja) 2007-01-11
KR101192136B1 (ko) 2012-10-16
PT1660115E (pt) 2011-08-24
JP4855253B2 (ja) 2012-01-18
KR20060079753A (ko) 2006-07-06
CA2526244C (en) 2012-03-20
CN1826134A (zh) 2006-08-30
WO2005014023A1 (en) 2005-02-17
EP1660115B1 (de) 2011-06-22
AU2004262909B2 (en) 2010-07-01
ES2369487T3 (es) 2011-12-01
SI1660115T1 (sl) 2011-10-28
DK1660115T3 (da) 2011-10-10

Similar Documents

Publication Publication Date Title
ATE513555T1 (de) Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
NO20063430L (no) Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
NO2014028I2 (no) Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom
DE60213114D1 (de) Herbizidzusammensetzung,umfassend herbizide verbindung in säureform und ansäuerndes mittel,applizierverfahren und herstellungsverfahren davon
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
EA200600164A1 (ru) Цеолиты для дозирования оксида азота
WO2004089396A3 (en) Anti-fungal peptidomimetics
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
FR2867684B1 (fr) Gel creme contenant de l'ivermectine
FR2889811B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
MA29030B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
ATE491710T1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7- dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
EP1663201A4 (de) Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660115

Country of ref document: EP